A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

The results position Hengrui to seek approval of the Zepbound-like drug in China and Kailera, a well-funded biotech startup, ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Researchers say findings indicate the drugs offer neuroprotective benefits beyond glucose control and weight loss. Experts say it’s a link that needs further study. Doctors have found a way to ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.